Jushi Q2 FY26 net loss narrows 41% to USD 7.33 million; revenue rises 10% to USD 71.3 million
Tax benefit and adjusted EBITDA
Income tax swung to a USD 976,000 benefit on federal rescheduling eliminating 280E for qualifying medical cannabis.
Adjusted EBITDA, a non-GAAP measure, slipped 3% to USD 13.34 million.
Q2 results show narrower loss and higher revenue
Jushi posted a net loss of USD 7.33 million, narrowing from a year earlier, as revenue rose 10% to USD 71.3 million.
Operating income fell 80% to USD 714,000 as operating expenses climbed 22% to USD 30.82 million. Interest expense eased 3% to USD 9.89 million.
Virginia market timing and Nevada domestication plan
Virginia’s adult-use market framework sets retail sales to start July 1, 2027.
Shareholders also backed a plan to domesticate the company in Nevada.
